AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$TEVA

Teva (TEVA) Q3 2026 Earnings Call Transcript

Teva (TEVA) reported Q3 2026 earnings, highlighting a 2% revenue decline but a 58.7% gross margin. Key products like AUSTEDO, UZEDY, and AJOVY showed strong growth, with UZEDY up 96%. The company discontinued a phase II study for emrusolmin and acquired BXCL501 to strengthen its neuroscience portfolio. Teva achieved investment-grade status and refinanced $4.9 billion in senior notes. The company expects peak sales of $1.5B-$2B for UZEDY and WELTRUZA.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva (TEVA) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The earnings release provides fresh guidance and performance metrics that were not previously public, offering traders actionable insight.

02

Market read

First‑time disclosure of Q3 2026 results and guidance makes this a high‑value trading event for TEVA and related pharma stocks.

03

What to watch

Potential headwinds from generic competition and regulatory timelines for pipeline assets.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Teva's Q3 2026 earnings call highlighted a strategic shift toward biopharma, new product launches (UZEDY, WELTRUZA), and a $4.9B senior note refinancing.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva reported Q3 2026 earnings with revenue of $4.4B, 2% decline, gross margin up to 58.7%, EBITDA up 7% and non‑GAAP EPS up 10%, plus product launches and guidance updates.

Expected impact

likely modest upside as investors price in higher margins and product growth

Evidence & confidence

Improved profitability metrics and new product momentum typically support a short‑term rally, though revenue softness tempers the move.

Market effects

Sector

Biopharma and generics sectors may see re‑rating as Teva's transition gains traction.

Regional

U.S. pharma stocks could experience modest buying pressure.

Global

Limited to companies with similar generics‑to‑biopharma shift.

Counterpoint

What could challenge this read

Revenue decline and reliance on a few key products could pressure the stock if growth stalls.

Key entities

  • company
    Teva Pharmaceutical Industries Ltd.

    Global generic and specialty pharma company.

Read at source← All news

StoryTeva posts Q3 2026 earnings, raises full‑year outlook and announces FDA approval for WELTRUZA

Also covered by

6 outlets

Related articles

NOV 4
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com2 min
NOV 4
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com6 min
NOV 3
$TEVAHighAI 9/10

Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%

Teva Pharmaceuticals (NYSE:TEVA) reported Q3 2026 revenues of $4.4B and adjusted EPS of $0.86, beating estimates. Gross margin rose to 58.7% due to a shift toward biopharma. Key products like AUSTEDO, UZEDY, and AJOVY drove growth. The company raised full-year guidance and announced FDA approval for WELTRUZA, a new schizophrenia treatment.

investing.com3 min
NOV 3
$TEVAMed

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva Pharmaceuticals and Samsung Bioepis agreed to license and commercialize two FDA-approved biosimilars in the U.S. Teva will handle sales, with Samsung retaining manufacturing. The deal includes upfront payments, milestones, and profit sharing. Closing is expected by the end of 2026, with rights to etanercept-ykro transferring at that time and infliximab-abda in Q3 2027.

pharmexec.com3 min